EP0474764A4 - Method to treat rheumatoid arthritis - Google Patents

Method to treat rheumatoid arthritis

Info

Publication number
EP0474764A4
EP0474764A4 EP19900909247 EP90909247A EP0474764A4 EP 0474764 A4 EP0474764 A4 EP 0474764A4 EP 19900909247 EP19900909247 EP 19900909247 EP 90909247 A EP90909247 A EP 90909247A EP 0474764 A4 EP0474764 A4 EP 0474764A4
Authority
EP
European Patent Office
Prior art keywords
rheumatoid arthritis
treat rheumatoid
treat
arthritis
rheumatoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900909247
Other versions
EP0474764A1 (en
Inventor
Dennis A. Carson
Jean Roudier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Publication of EP0474764A1 publication Critical patent/EP0474764A1/en
Publication of EP0474764A4 publication Critical patent/EP0474764A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
EP19900909247 1989-05-31 1990-05-31 Method to treat rheumatoid arthritis Withdrawn EP0474764A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35978289A 1989-05-31 1989-05-31
US359782 1994-12-20

Publications (2)

Publication Number Publication Date
EP0474764A1 EP0474764A1 (en) 1992-03-18
EP0474764A4 true EP0474764A4 (en) 1992-11-19

Family

ID=23415246

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900909247 Withdrawn EP0474764A4 (en) 1989-05-31 1990-05-31 Method to treat rheumatoid arthritis

Country Status (4)

Country Link
EP (1) EP0474764A4 (en)
JP (1) JPH05500653A (en)
CA (1) CA2056450A1 (en)
WO (1) WO1990014835A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
US5719064A (en) * 1992-08-31 1998-02-17 Oklahoma Medical Research Foundation Peptide diagnostics and therapeutics for spondyloarthropathies
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
CA2188582A1 (en) * 1994-05-20 1995-11-30 Dennis A. Carson Method and reagents for the treatment of rheumatoid arthritis
US7094597B1 (en) 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7608683B2 (en) 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1355923B1 (en) 2000-11-01 2012-03-07 The Regents of The University of California Immunomodulatory peptides derived from heat shock proteins and uses thereof
US7074893B2 (en) 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
EP2316844A3 (en) * 2003-05-21 2011-07-20 Biotech Tools S.A. Peptide complex
DK1625148T3 (en) 2003-05-21 2013-01-14 Biotech Tools Sa peptide Complex
US8658603B2 (en) * 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP3463482B1 (en) * 2016-06-07 2021-10-06 The Brigham and Women's Hospital, Inc. Methods relating to t peripheral helper cells in autoantibody-associated conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744A (en) * 1977-09-28 1979-04-11 Sanderson A R Immunological preparations containing major histocompatibility complex antigen
WO1980001986A1 (en) * 1979-03-27 1980-10-02 A Sanderson Improvements in or relating to immunological preparations
EP0286447A2 (en) * 1987-04-09 1988-10-12 The Board Of Trustees Of The Leland Stanford Junior University Method and agents relating to prophylactic treatment of autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744A (en) * 1977-09-28 1979-04-11 Sanderson A R Immunological preparations containing major histocompatibility complex antigen
WO1980001986A1 (en) * 1979-03-27 1980-10-02 A Sanderson Improvements in or relating to immunological preparations
EP0286447A2 (en) * 1987-04-09 1988-10-12 The Board Of Trustees Of The Leland Stanford Junior University Method and agents relating to prophylactic treatment of autoimmune diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS & RHEUMATISM, vol. 30, no. 11, November 1987, pages 1205-1213, Am. Rheumatism Ass, NEW YORK, US; P.K. GREGERSEN et al.: "The shared epitope hypothesis" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 82, August 1985, pages 5165-5169; T. SPIES et al.: "Structural organization of the DR subregion of the human major histocompatibility complex" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 86, July 1989, pages 5104-5108, US; J. ROUDIER et al.: "Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110" *
See also references of WO9014835A1 *
THE JOURNAL OF IMMUNOLOGY, vol. 142, no. 5, 15th March 1989, pages 1743-1747, The American Association of Immunologists, Baltimore, US; H.-T. KAO et al.: "Molecular analysis of the HLA class II genes in two DRw6- related haplotypes, DRw13 DQw1 and DRw14 DQw3" *

Also Published As

Publication number Publication date
EP0474764A1 (en) 1992-03-18
CA2056450A1 (en) 1990-12-01
WO1990014835A1 (en) 1990-12-13
JPH05500653A (en) 1993-02-12

Similar Documents

Publication Publication Date Title
IL107050A0 (en) Method of treating rheumatoid arthritis with type ii collagen
EP0301924A3 (en) Waste water treating process
EP0474764A4 (en) Method to treat rheumatoid arthritis
GB2233996B (en) Well treatment method
GB2215635B (en) Emulsification method
PL286707A1 (en) Method of obteining tetraniture
GB8829830D0 (en) Method for treating water
GB8913090D0 (en) Method
GB2219503B (en) Treatment of arthritis
PL278104A1 (en) N-sulfonylo-carbamides production method
EP0420428A3 (en) Method of treatment of rheumatoid arthritis using phytic acid
GB8717755D0 (en) Treating rheumatoid arthritis
EP0327273A3 (en) Dyeimage forming method
GB8810179D0 (en) Processing method
RU1785688C (en) Method of psoriatic arthritis treatment
EP0425676A4 (en) Digitizing method
GR900100777A (en) Improved method for useful diazinylpiperidines
EP0662838A4 (en) Method of treating rheumatoid arthritis with type ii collagen.
GB8912239D0 (en) Treating method
PH24781A (en) A method of treating rheumatiodal arthritis
CS640089A1 (en) Method of 2-ethyl-6-methyl-n-/1-methoxy-2-propyl/chlorethanilide
IE891751L (en) Treatment of arthritis
GB8403142D0 (en) Treatment of rheumatoid arthritis
GB8811832D0 (en) Treating method
GB8610698D0 (en) Treatment of rheumatoid arthritis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920928

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941201